Laetrile treatment for cancer (2015)

Peer-Reviewed Study · Milazzo S, Horneber M (Cochrane Database Syst Rev 2015;(4):CD005476) · April 28, 2015

Milazzo S et al., 2015-04-28: Cochrane review (Milazzo et al., fourth edition) of laetrile/amygdalin for cancer. No sound clinical data support benefit, and the risk of cyanide poisoning – especially after oral ingestion – makes the risk-benefit balance 'unambiguously negative'.

The claims that laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data.

Abstract (AUTHORS' CONCLUSIONS)

Milazzo S et al., 2015-04-28: Cochrane review (Milazzo et al., fourth edition) of laetrile/amygdalin for cancer. No sound clinical data support benefit, and the risk of cyanide poisoning – especially after oral ingestion – makes the risk-benefit balance 'unambiguously negative'. Funder: external – European Commission FP5 CAM-Cancer project (QLRT-2001-00786), Cochrane Gynaecological Cancer Group, and Deutsche Krebshilfe project 'Arbeitsgruppe Biologische Krebstherapie' (70-301); review states funders had no role. Conflicts: authors certify no affiliations with a financial interest in the subject. Product: laetrile/amygdalin (amygdalin sold as 'Laetrile', often by unlicensed suppliers; no manufacturer named). Comparator: no RCT evidence of benefit; case series only. PMC6513327. Study type: review.